Aliskiren versus hydrochlorothiazide with optional amlodipine in essential hypertension

Phase 3, randomised, double-blind trial of aliskiren, hydrochlorothiazide and amlodipine in essential hypertension (2 arms), sponsored by Novartis. Primary endpoints: Change from baseline in mean sitting diastolic blood pressure, Non-inferiority of aliskiren regimen versus hydrochlorothiazide regimen for mean sitting diastolic blood pressure reduction and 1 more. Started Feb 2005; status: completed.